Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Activation of T cells to the capsid of adeno-associated virus (AAV) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of hemophilia B. To further investigate this kind of toxicity, we evaluated T-cell responses to AAV capsids after intramuscular injection of vectors into mice and nonhuman primates. High levels of T cells specific to capsids of vectors based on AAV2 and a phylogenetically related AAV variant were detected. Vectors from other AAV clades such as AAV8 (ref. 3), however, did not lead to activation of capsid-specific T cells. Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG). Evaluation of natural and engineered AAV variants showed direct correlations between heparin binding, uptake into human dendritic cells (DCs) and activation of capsid-specific T cells. The role of heparin binding in the activation of CD8(+) T cells may be useful in modulating the immunogenicity of antigens and improving the safety profile of existing AAV vectors for gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the VP3 VIII variable region of AAV8 is not involved in HSPG recognition by the cell surface receptor57.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [57]
In the citing paper
“However, this does not apply here because AAV8 does not elicit a CD8+ T cell response against capsid in mice and because the vector dose was anyhow too low to generate such a response.25,66,67”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [66]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“dtd" [ ]> Activation of T cells to the capsid of adeno-associated virus (AAV) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of hemophilia”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Self-citationSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Self-citationThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 1×
“The VP3 protein comprises the structural backbone for the particle architecture as well as the majority of variable domains between AAV2 and AAV8 (refs”
BackgroundIdentification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundOpie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundAdeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323
Self-citationHalbert, C. L., Allen, J. M., & Miller, A. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6615-6624.2001 · Cited by 314 · cited 1×
“All members of AAVs from Clades A, C, D, E and F are missing the RXXR motif, and those that have been studied do not bind heparin with the avidity of AAV2 (ref”
BackgroundWilson, N. S., & Villadangos, J. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86007-3 · Cited by 176 · cited 1×
“Pathways by which this occurs begin with endocytotic or phagocytotic uptake followed by a series of proteolytic steps and eventual loading of peptides onto MHC class I complexe”
Background
Cited by
Items 101–200 of 208
Muscle as a Target for Supplementary Factor IX Gene Transfer
Hoffman, B. E., Dobrzynski, E., Wang, L., Hirao, L., Mingozzi, F., Cao, O., & Herzog, R. W. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.042 · Cited by 44
Self-citationvan den Berg, F. T., Aminake, M. N., Ali, S. A., Scott, T. A., Mapengo, R. E., Mutsvunguma, L. Z., Mkhize, N. N., Lambson, B. E., Kgagudi, P., Crowther, C. E., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.002 · Cited by 47
“Serotype 8 AAVs (AAV8)(48) were also generated for use in in vivo studies, as they were previously reported to mediate efficient gene transfer to murine muscle(49) with reduced immunogenicity.(50) Purified AAVs were used to infect HEK293T cells at approximately 10(5) viral genome copies per cell, and media were collec…”
MethodGregorevic, P., Schultz, B. R., Allen, J. M., Halldorson, J. B., Blankinship, M. J., Meznarich, N. A., Kuhr, C. S., Doremus, C., Finn, E., Liggitt, D., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.116 · Cited by 40
Adjunctive β2‐agonists reverse neuromuscular involvement in murine Pompe disease
Li, S., Sun, B., Nilsson, M. I., Bird, A., Tarnopolsky, M. A., Thurberg, B. L., Bali, D. S., & Koeberl, D. D. (2012) · The FASEB Journal · doi:10.1096/fj.12-207472 · Cited by 42
Immune Responses to AAV in Canine Muscle Monitored by Cellular Assays and Noninvasive Imaging
Wang, Z., Storb, R. F., Lee, D., Kushmerick, M. J., Chu, B., Berger, C., Arnett, A. L. H., Allen, J. M., Chamberlain, J. S., Riddell, S. R., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.294 · Cited by 46
Lin, A. Z., & Balazs, A. B. (2018) · Retrovirology · doi:10.1186/s12977-018-0449-7 · Cited by 42
“cells, due to lack of heparin binding which likely leads to uptake by dendritic cells [75], and may induce immune tolerance [10, 76].”
BackgroundThe Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives
Jacobs, F., Gordts, S. C., Muthuramu, I., & Geest, B. D. (2012) · Pharmaceuticals · doi:10.3390/ph5121372 · Cited by 46
“product [106].”
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
“However, the VP3 VIII variable region of AAV8isnotinvolvedinHSPGrecognitionbythecellsurfacereceptor 57 .”
Wu, T.-L., Li, H., Faust, S. M., Chi, E., Zhou, S., Wright, F., High, K. A., & Ertl, H. C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.218 · Cited by 38
Jayandharan, G. R., Zhong, L., Sack, B. K., Rivers, A. E., Li, M., Li, B., Herzog, R. W., & Srivastava, A. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.100 · Cited by 38
“It is also noteworthy that the AAV8 capsid is less immunogenic than the AAV2 capsid (Vandenberghe et al. , 2006), and the long-term efficacy and safety of AAV8 vectors have been documented in liver-directed gene therapy in dogs (Wang et al. , 2005).”
Okada, T., & Takeda, S. (2013) · Pharmaceuticals · doi:10.3390/ph6070813 · Cited by 45
“(HSPG) receptor, which would permit virion shuttling into a DC pathway, as cross-presentation [85].”
BackgroundProgress and Prospects: prospects of repeated pulmonary administration of viral vectors
Sinn, P. L., Burnight, E. R., & McCray, P. B. (2009) · Gene Therapy · doi:10.1038/gt.2009.87 · Cited by 35
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Chung, C. W., Kudchodkar, S. B., Chung, C. N., Park, Y. K., Xu, Z., Pardi, N., Abdel‐Mohsen, M., & Muthumani, K. (2023) · Antibodies · doi:10.3390/antib12030046 · Cited by 40
“Serotypes like AAV8, which lack heparin-binding activity, did not induce CTL responses [48].”
BackgroundArnett, A. L. H., Beutler, L. R., Quintana, A., Allen, J., Finn, E., Palmiter, R. D., & Chamberlain, J. S. (2013) · Gene Therapy · doi:10.1038/gt.2012.60 · Cited by 34
Trepel, M., Körbelin, J., Spies, E., Heckmann, M. B., Hunger, A., Fehse, B., Katus, H. A., Kleinschmidt, J. A., Müller, O. J., & Michelfelder, S. (2015) · Gene Therapy · doi:10.1038/gt.2015.52 · Cited by 38
Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
High, K. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.466 · Cited by 32
“A third hypothesis has raised the possibility that a specific motif within the dominant protein of the AAV capsid favors receptor-mediated uptake of vector by human dendritic cells, with activation of capsid-specific CD8 T cells occurring on that basis.(14) This hypothesis, to be tested in an upcoming clinical trial o…”
BackgroundIt's all about the clothing: capsid domination in the adeno‐associated viral vector world
Arruda, V. R., & Xiao, W. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02262.x · Cited by 38
Vliet, K. V., Mohiuddin, Y., McClung, S. H., Blouin, V., Rolling, F., Moullier, P., Agbandje‐McKenna, M., & Snyder, R. O. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.03.020 · Cited by 35
TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
Kumar, S. R. P., Biswas, M., Cao, D., Arisa, S., Muñoz-Melero, M., Lam, A. K., Piñeros, A. R., Kapur, R., Kaisho, T., Kaufman, R. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.029 · Cited by 31
“25,66,67 The initial activation signal and resulting chemokine gradients that trigger the in fl ux of IL-1-producing pDCs cells remains to be discovered.”
Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
“91 The AAV vector used in this trial was based on a so-called self-complementary design, 82 which was believed to overcome one of the limiting steps in AAV transduction, namely the single-stranded DNA to double-stranded transcription-competent double-stranded DNA conversion.”
Toll-like Receptors Impact on Safety and Efficacy of Gene Transfer Vectors
Hensley, S. E., & Amalfitano, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300217 · Cited by 36
Recent Progress in Gene Therapy for Hemophilia
Chuah, M., Nair, N., & VandenDriessche, T. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.088 · Cited by 34
“Interestingly, its uptake by dendritic cells may be reduced compared to conventional AAV2 vectors, resulting in reduced T-cell activation (Vandenberghe et al. , 2006).”
Ussher, J. E., & Taylor, J. A. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.087 · Cited by 30
“A study that evaluated natural and engineered AAV variants showed direct correlations between heparin binding, uptake into MoDCs, and activation of a capsid-specific T cell response, although rAAV2/6 was not included in this study (Vandenberghe et al. , 2006).”
Preclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 36
Flageul, M., Aubert, D., Pichard, V., Nguyen, T. H., Nowrouzi, A., Schmidt, M., & Ferry, N. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1343 · Cited by 31
“Although an immune response directed to epitopes of the vector capsid precluded long-term expression of the therapeutic gene in transduced hepatocytes, this trial demonstrated the safety and feasibility of this strategy [4,5].”
BackgroundAAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 32
“Moreover, AAV8 capsid cannot effectively activate cytotoxic T cells in mice or non-human primates, presumably due to an attenuated capacity of interaction with dendritic cells [137].”
BackgroundRaj, D., Davidoff, A. M., & Nathwani, A. C. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.48 · Cited by 27
Choijilsuren, G., Jhou, R., Chou, S.-F., Chang, C.-J., Yang, H., Chen, Y.-Y., Chuang, W., Yu, M., & Shih, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14573-9 · Cited by 27
Muscle‐directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors
Wang, L., Louboutin, J. P., Bell, P. L., Greig, J. A., LI, Y., WU, D., & Wilson, J. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04491.x · Cited by 32
Self-citationHe, Y., Weinberg, M. S., Hirsch, M., Johnson, M. C., Tisch, R., Samulski, R. J., & Li, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.065 · Cited by 26
“It has been demonstrated that heparan binding directs activation of T cells against AAV 2 capsid (Vandenberghe et al., 2006).”
BackgroundGraham, T., McIntosh, J., Work, L. M., Nathwani, A. C., & Baker, A. H. (2008) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-6-9 · Cited by 27
“AAV8 in particular shows promise in this regard since it is less immunogenic than AAV-2 capsids [8].”
Ancestral Library Identifies Conserved Reprogrammable Liver Motif on AAV Capsid
Zinn, E. M., Unzu, C., Schmit, P. F., Turunen, H., Zabaleta, N., Sanmiguel, J. C., Fieldsend, A., Bhatt, U., Diop, C. T., Merkel, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100803 · Cited by 30
Self-citationPreclinical Development of New Therapy for Glycogen Storage Diseases
Sun, B., Brooks, E., & Koeberl, D. D. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630132253 · Cited by 29
“Furthermore, vectors packaged with the novel AAV serotypes elicit a lower immune response than the original AAV2 capsid [17].”
BackgroundActivation of CFTR-specific T Cells in Cystic Fibrosis Mice Following Gene Transfer
Limberis, M. P., Figueredo, J. M., Calcedo, R., & Wilson, J. M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300210 · Cited by 24
Self-citationHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Pleticha, J., Heilmann, L. F., Evans, C. H., Asokan, A., Samulski, R. J., & Beutler, A. S. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-54 · Cited by 21
“The choice of AAV serotype may affect the cellular immunity through direct, antigen presenting cell-independent activation of T-lymphocytes by an AAV capsid [48,49].”
BackgroundAdeno‐Associated Virus Vector–Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver
Junge, N., Mingozzi, F., Ott, M., & Baumann, U. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000703 · Cited by 23
“org can result in loss of transgene expression (39), whereas animals do not (40).”
BackgroundKoppanati, B. M., Li, J., Xiao, X., & Clemens, P. R. (2009) · Gene Therapy · doi:10.1038/gt.2009.71 · Cited by 25
Preclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
Wang, Z., Halbert, C. L., Lee, D., Butts, T. M., Tapscott, S. J., Storb, R. F., & Miller, A. D. (2014) · Gene Therapy · doi:10.1038/gt.2014.4 · Cited by 18
Viral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 21
Gene Therapy for Misfolding Protein Diseases of the Central Nervous System
Sebastián, W. S., Samaranch, L., Kells, A. P., Forsayeth, J., & Bankiewicz, K. S. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0191-8 · Cited by 20
“AAV2 is the most common vector used in gene therapy for neurological disease, mainly, because AAV2 is a neuronspecific serotype with no described adverse effects in the CNS, although previous studies report development of immune response after AAV2 delivery into rat liver [31].”
BackgroundDevelopments in the treatment of hemophilia B: focus on emerging gene therapy
Gray, J. T., Cancio, M., Reiss, U. M., Nathwani, A. C., & Davidoff, A. M. (2013) · The Application of Clinical Genetics · doi:10.2147/tacg.s31928 · Cited by 19
Kumar, S. R. P., Xie, J., Hu, S., Ko, J., Huang, Q., Brown, H. C., Srivastava, A., Markusic, D. M., Doering, C. B., Spencer, H. T., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.001 · Cited by 16
“In non-human primate andmouse studies, CD8 T cell responses against capsid were observed by day 7 after gene transfer, especially for capsid with heparin binding sites, as is the case for AAV3.(31,41) However, our vector with an expression cassette that lacks CpGmotifs within the hFIX cDNAdid not elicit a detectable I…”
BackgroundSelf-citationThe HLA class-II immunopeptidomes of AAV capsids proteins
Brito-Sierra, C. A., Lannan, M. B., Siegel, R. W., & Malherbe, L. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067399 · Cited by 17
Gene therapy: therapeutic applications and relevance to pathology
Both, G. W., Alexander, I. E., Fletcher, S., Nicolson, T. J., Rasko, J. E. J., Wilton, S. D., & Symonds, G. P. (2011) · Pathology · doi:10.1097/pat.0b013e32834b1dad · Cited by 17
“since the AAV-2 capsid is more likely to induce a cytotoxic T cell response following binding to heparin sulphate proteoglycan and uptake by dendritic cells.(119) Other serotypes such as AAV-8 and AAV-6 are degraded more rapidly in hepatocytes”
BackgroundXicluna, R., Schwalie, P. C., Bell, E., von Tell, D., Steiner, G., Seeger, E., Heeren, J. J. F., Turksma, A. W., Pouw, R. B., Schwandt, T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101551 · Cited by 16
“Vandenberghe et al. 39 have previously shown that AAV2 binds to DCs more efficiently than AAV8 due to its heparin binding site, also impacting the uptake by other cell types.”
Xu, D., & Walker, C. M. (2011) · Journal of Virology · doi:10.1128/jvi.05375-11 · Cited by 14
“Intramuscular delivery of rAAV1 -Gal and rAAV2 -Gal induced CD8 T-cell responses, even though the latter vector is thought to transduce dendritic cells inefficiently (7, 13).”
BackgroundResultHepatic AAV Gene Transfer and the Immune System: Friends or Foes?
Herzog, R. W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.96 · Cited by 17
Choppara, S., Ganga, S., Manne, R., Dutta, P., Singh, S., & Santra, M. K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005354 · Cited by 13
“Interestingly, a few previous reports have also suggested that the RXXR motif could have possible cellular roles like heparin binding for a T-cell response following adeno-associated virus infection or that the RXXR motif could be recognized as a proteolytic cleavage site (37, 38).”
BackgroundNguyen, T. H., & Ferry, N. (2007) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.1.1.155 · Cited by 13
Gerpe, M. C. R., van Lieshout, L. P., Domm, J. M., Ingrao, J. C., Datu, J., Walsh, S. R., Yu, D. L., de Jong, J., Krell, P. J., & Wootton, S. K. (2019) · Viruses · doi:10.3390/v11111061 · Cited by 13
“The presence of JSRV-like and ENTV-like endogenous betaretroviral sequences in the sheep genome that share high nucleotide and amino acid identities with exogenous JSRV and ENTV [59] has tolerized the sheep immune system against these exogenous viruses [67,68].”
VandenDriessche, T., & Chuah, M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.221 · Cited by 11
“This AAV8 serotype can efficiently transduce hepatocytes, does not interact as effi-ciently with antigen-presenting cells as AAV2, and has limited cross-reactivity with preexisting anti-AAV2 antibodies (Gao et al ., 2002; Vandenberghe et al ., 2006; VandenDriessche et al ., 2007).”
Zinkernagel, M. S., McMenamin, P. G., Forrester, J. V., & Degli‐Esposti, M. A. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.04.001 · Cited by 11
Gene Therapy for Cardiac Arrhythmias: A Dream Soon to Come True?
Donahue, J. K. (2007) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2007.00806.x · Cited by 10
Mason, J. B., Gurda, B. L., Wettere, A. J. V., Engiles, J. B., Wilson, J. M., & Richardson, D. W. (2015) · Equine Veterinary Journal · doi:10.1111/evj.12547 · Cited by 10
Self-citationAdvances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9
Gene therapy as a vaccine for HIV-1
Berkhout, B., & Sanders, R. W. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707177 · Cited by 10
“The choice of an AAV serotype of which the capsid lacks heparin-binding activity may circumvent immunological responses that will prevent long-term transgene expression [52].”
BackgroundSherpa, C., & Grice, S. F. J. L. (2020) · Current HIV Research · doi:10.2174/1570162x18666200210121339 · Cited by 8
Monkey business for hemophilia management
Hortelano, G. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.02.016 · Cited by 8
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
Sun, W., Wu, Y., & Ying, T. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105867 · Cited by 9
Kim, Y., Kim, E., Oh, S., Yoon, Y.-E., & Jang, J. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.034 · Cited by 7
“41 Thus, disguising the HSPG binding spike locus by displaying the LATQVGQKTA motif might contribute to the ability of AAVr3.”
VandenDriessche, T. (2009) · Blood · doi:10.1182/blood-2009-07-228510 · Cited by 7
Efficient AAV Vector Production System: Towards Gene Therapy For Duchenne Muscular Dystrophy
Okada, T. (2013) · InTech eBooks · doi:10.5772/53023 · Cited by 7
“Addi‐ tional findings suggest that T-cell activation requires AAV2 capsid binding to the heparan sulfate proteoglycan (HSPG) receptor, which would permit virion shuttling into a DC path‐ way, as cross-presentation.[54] Exposure to vectors from other AAV clades, such as AAV8, did not activate capsid-specific T-cells.”
BackgroundAAV-based gene delivery of antimicrobial peptides to combat drug-resistant pathogens
Baindara, P., Dinata, R., Boosani, C. S., Mandal, S. M., & Green, J. A. (2025) · Applied and Environmental Microbiology · doi:10.1128/aem.01702-24 · Cited by 5
“The serotype-specific immune response can also be managed easily as reported in the case of AAV2 and AAV8 where the preferred receptor is hairpin proteoglycans for AAV2 that may elicit a greater T-cell response (50).”
Masri, S., Carré, L., Jaulin, N., Vandamme, C., Couzinié, C., Guy‐Duché, A., Dupont, J.-B., Pereira, A., Charpentier, É., David, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310447 · Cited by 6
Single-dose AAV vector gene immunotherapy to treat food allergy
Gonzalez-Visiedo, M., Li, X., Muñoz-Melero, M., Kulis, M. D., Daniell, H., & Markusic, D. M. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.008 · Cited by 4
“However, these studies used an AAV2 capsid that is less efficient at transducingmouse hepatocytes(47) and can transduce antigen-presenting cells.(58) The hepatic tropism of an AAV8 capsid in mice is sufficient to restrict antigen expression to hepatocytes even with an ubiquitous EF1a promoter.”
A comparative study of hFIX expression mediated by rAAV8 and rAAV1 administrated intramuscularly
Cao, Z.-Y., Zheng, P., & Lin, Y.-T. (2007) · Cytotherapy · doi:10.1080/14653240701519004 · Cited by 5
Li, B., Guo, W., Zhang, F., Liu, M., Wang, S., Liu, Z., Xiang, S., & Zeng, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180276 · Cited by 4
Adeno‐associated Viral Vectors in Gene Therapy
Ling, C., Zhong, L., & Srivastava, A. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0005738.pub3 · Cited by 6
Preclinical Study Design for rAAV
Flotte, T. R., Conlon, T. J., & Mueller, C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_14 · Cited by 3
6. Themenbereich somatische Gentherapie: Translationale und klinische Forschung
Fehse, B., & Domasch, S. (2015) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783845246956-210 · Cited by 5
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
Enhanced cellular secretion of AAV2 by expression of foreign viral envelope proteins
Kotterman, M. A., Koerber, J. T., Nam, J.-S., Cho, Y.-H., Kim, S., Jang, J.-H., & Lim, K. (2014) · Biochemical Engineering Journal · doi:10.1016/j.bej.2014.09.015 · Cited by 2
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
AAV-Based Targeting Gene Therapy
Shi, W., Yu, M., & Qian, Q. (2008) · American Journal of Immunology · doi:10.3844/ajisp.2008.51.65 · Cited by 2
Lee, W. I., Khim, M., Im, I. R., Shin, O. S., Park, J. W., Choo, S., Yun, T.-J., Kim, S. W., & Lee, H. (2011) · Tissue and Cell · doi:10.1016/j.tice.2010.12.006 · Cited by 2
Progress and Challenges in AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy
Takeda, S., & Ok, T. (2011) · InTech eBooks · doi:10.5772/18624 · Cited by 2
“Additional findings suggest that T-cell activation requires AAV2 capsid binding to the heparan sulfate proteoglycan (HSPG) receptor, which would permit virion shuttling into a DC pathway, as cross-presentation (Vandenberghe et al., 2006).”
Amberg, B., Köchl, F., Kumpesa, N., Prasad, M. K., Bochner, F., Hernandez-Obiols, M., Otteneder, M. B., Stalder, L., Shaffo, F. C., Nowrouzi, A., et al. (2026) · Gene Therapy · doi:10.1038/s41434-026-00600-w · Cited by 1
“Given that lipid metabolism is crucial for viral entry, replication, and immune evasion [91 – 93], our results raise the possibility that rAAV vectors may engage similar host pathways to optimize transgene expression.”
Gene Delivery to Cardiovascular Tissue
Masson, R., Nicklin, S. A., & Baker, A. H. (2009) · Springer eBooks · doi:10.1007/978-1-84882-637-3_2 · Cited by 1
The State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
Cell‐Specific Targeting of Fusion Proteins through Heparin Binding
Wang, J., Ma, Z., & Loeb, J. A. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch27
Gene Therapy Trials in Hemophilia A and B
High, K. A. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch41
IN UTERO GENE DELIVERY OF AAV VECTORS FOR EFFICIENT TREATMENT OF MUSCLE DISORDERS
Koppanati, B. M. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Müller, O. J., & Katus, H. A. (2008) · Springer eBooks · doi:10.1007/978-3-540-78709-9_9
“Interestingly, the same region is also involved in uptake of AAV-2 in human dendritic cells and elucidation of a specific T-cell response against AAV capsids (Vandenberghe et al. 2006).”
BackgroundYu, C.-Y., Wang, B., Wang, Z., Cao, Z., Li, J., & Xiao, X. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.556
Progress and challenges in gene therapy for Crigler–Najjar syndrome
Aronson, S. J., Beuers, U. H., & Bosma, P. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1100991 · Cited by 1
Moda, F. (2010) · BOA (University of Milano-Bicocca) · Cited by 1
[Cellular immunotoxicity of rAAV gene medicine and possible solutions].
Diao, Y., Qizhao, W., Xiao, W., & Xu, R. (2010) · PubMed
Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders
Casy, W., Ling, Q., Shaffo, F. C., Sinnett, S. E., & Gray, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00010-6 · Cited by 1
Graham, T., McIntosh, J., Work, L. M., Nathwani, A. C., & Baker, A. H. (2015)
Adeno‐associated Viral Vectors in Gene Therapy
Li, Z., & Srivastava, A. (2007) · Wiley eBooks · doi:10.1002/9780470015902.a0005738.pub2
High, K. A. (2023) · PubMed Central · Cited by 2
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders
Ling, Q., Boitnott, A., Garza, I. T., Casy, W., Shaffo, F. C., Sinnett, S. E., & Gray, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00007-8
The Use of AAV Vector-based Gene Therapy in the Treatment of Ophthalmic Diseases. Literature Review
Batyrova, Z. A., Murtazalieva, A. S., Ramazanova, J. M., & Batchaev, A. S. ‐. (2025) · Ophthalmology in Russia · doi:10.18008/1816-5095-2025-2-244-250
Asim, M. A., Altaf, A., Sohail, A., Arshad, M., Noreen, F., Raza, I., Muneer, H., Hasnain, M. M., Sufyan, R., & Ullah, I. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011551
Zhang, Y., Shi, Y., Zhou, X., Han, X., Wang, F., Zhang, J., Luo, J., Wang, X., Wang, Y., Ji, D., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01166
Metadata
- Authors
- Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., Grant, R. L., Gao, G., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Wilson, James M
- ORCID
- Venue
- Nature Medicine
- Published
- 2006-07-16
- Volume
- 12
- Issue
- 8
- Pages
- 967-971
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2080951809
- Cited by
- 208
- References
- 17
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 9 · 2016: 3 · 2015: 15 · 2014: 6 · 2013: 14 · 2012: 7
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Science Foundation
- GlaxoSmithKline
- National Heart, Lung, and Blood Institute (P01-HL-05407)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK047757)
- National Institute of Biomedical Imaging and Bioengineering
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV2, AAV capsid, T cell activation, heparin binding, heparan sulfate proteoglycans, VP3, dendritic cell uptake, CD8+ T cells, AAV8, hepatotoxicity, hemophilia B, non-human primates
- MeSH terms
- Dependovirus, Animals, Capsid, Dendritic Cells, Genetic Markers, Genetic Vectors, Cricetinae, HeLa Cells, Heparin, Humans, Interferon-gamma, Kinetics, Leukocytes, Mononuclear, Lymphocyte Activation, Macaca fascicularis, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Serotyping, T-Lymphocytes, Time Factors, Interleukin-4, Granulocyte-Macrophage Colony-Stimulating Factor, CHO Cells, Protein Structure, Tertiary, Capsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.